Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
407,379

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 40.91% and 11.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merit Medical (MMSI) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to gain traction from robust Peripheral Intervention arm and solid international presence. Forex, although, remains a concern.

Debanjana Dey headshot

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

by Debanjana Dey

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.

Zacks Equity Research

Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss

by Zacks Equity Research

Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.

Zacks Equity Research

Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat

by Zacks Equity Research

Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.

Zacks Equity Research

Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 40.54% and 7.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Merit Medical (MMSI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Trina Mukherjee headshot

Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch

by Trina Mukherjee

Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.

Zacks Equity Research

Merit Medical (MMSI) Up 0.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 25.58% and 3.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merit Medical (MMSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.

Zacks Equity Research

Cardinal Health (CAH) Unveils New Logistics Management Tool

by Zacks Equity Research

Cardinal Health's (CAH) company, OptiFreight Logistics, launched TotalVue Analytics to help healthcare supply chain leaders to drive cost savings.

Zacks Equity Research

DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business

by Zacks Equity Research

DENTSPLY (XRAY) acquires Byte to strengthen presence in the lucrative clear aligner space.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.

Zacks Equity Research

LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay

by Zacks Equity Research

Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.

Zacks Equity Research

Integra (IART) Sells Unprofitable Arm to Focus on Core Business

by Zacks Equity Research

Integra (IART) does not expect the selloff to have a material impact on its 2020 results.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Zacks Equity Research

Merit Medical Systems (MMSI) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Merit Medical Systems (MMSI) has been struggling lately, but the selling pressure may be coming to an end soon.